inflammatori
bowel
diseas
ibd
ulcer
coliti
uc
crohn
diseas
cd
complex
caus
involv
genet
environment
geograph
factor
thought
result
inappropri
ongo
activ
mucos
immun
cell
driven
presenc
abnorm
gut
microbiota
result
chronic
inflamm
gastrointestin
tract
git
shown
infiltr
lymphocyt
respons
gut
microbiota
associ
loss
toler
intestin
mucosa
current
ibd
treatment
includ
antiinflammatori
drug
induc
maintain
remiss
cur
moreov
use
accompani
sever
side
effect
allerg
reaction
chill
fever
urticaria
liver
problem
context
biolog
agent
probiot
antiinflammatori
properti
propos
tool
prevent
treatment
ibd
probiot
use
studi
today
belong
lactic
acid
bacteria
lab
group
mainli
compos
lactobacilli
isol
human
git
howev
probiot
may
also
includ
bifidobacterium
streptococcu
strain
member
lactobacillu
genu
therapeut
properti
improv
normal
microbiota
prevent
infecti
diseas
food
allergi
stabilis
gut
mucos
barrier
modul
innat
adapt
immun
respons
hand
lactococcu
genu
receiv
littl
attent
respect
probiot
activ
mainli
bacteria
usual
consid
commens
howev
lactococcu
lacti
strain
constant
transit
git
ingest
ferment
dairi
veget
product
studi
shown
exert
benefici
effect
among
nishitani
et
al
demonstr
l
lacti
subsp
cremori
fc
possess
potent
antiinflammatori
activ
oral
administr
l
lacti
fc
reduc
inflammatori
cytokin
product
well
induc
nitric
oxid
express
dextran
sulphat
sodium
dss
induc
coliti
mice
suggest
oral
administ
l
lacti
fc
may
benefici
impact
human
ibd
thu
object
studi
evalu
potenti
mechan
involv
antiinflammatori
effect
l
lacti
strain
still
poorli
understood
none
test
l
lacti
strain
induc
secret
background
level
indic
induc
inflammatori
event
iec
figur
b
investig
whether
l
lacti
antiinflammatori
effect
iec
abil
strain
block
secret
induc
analys
cell
secret
baselin
level
increas
stimul
none
live
cell
fraction
abl
reduc
secret
figur
howev
supernat
ncdo
cultur
reduc
product
figur
wherea
supernat
show
similar
effect
thu
antiinflammatori
role
l
lacti
vitro
straindepend
base
vitro
result
l
lacti
ncdo
select
test
vivo
effect
oral
administr
strain
test
murin
model
chemic
induc
coliti
remiss
period
second
coliti
cycl
experiment
protocol
mimic
remiss
activ
period
ibd
shown
figur
bodi
weight
mice
significantli
decreas
dss
treatment
compar
bodi
weight
watertr
mice
control
group
dss
withdraw
mice
gradual
recov
bodi
weight
experiment
group
treatment
l
lacti
ncdo
contribut
signific
chang
weight
gain
figur
reduct
colon
length
day
dss
dss
group
also
observ
figur
nevertheless
end
experi
day
oral
treatment
l
lacti
led
restor
colon
length
figur
mice
consum
l
lacti
exhibit
significantli
reduc
clinic
symptom
macroscop
inflammatori
score
recoveri
phase
upon
coliti
induct
figur
despit
sever
inflamm
second
coliti
cycl
find
suggest
l
lacti
administ
vivo
antiinflammatori
effect
abil
l
lacti
ncdo
prevent
dssinduc
colon
damag
evalu
histolog
level
colon
section
mice
control
group
intact
epithelium
welldefin
crypt
length
neutrophil
infiltr
mucos
submucos
layer
figur
contrast
colon
tissu
dsstreat
mice
show
sever
inflammatori
lesion
throughout
mucosa
submucosa
figur
oral
administr
l
lacti
ncdo
amelior
histolog
damag
second
coliti
cycl
immedi
improv
inflammatori
statu
gut
mucosa
day
figur
secretori
iga
evalu
mous
faec
day
level
siga
increas
second
coliti
cycl
oral
administr
l
lacti
ncdo
maintain
siga
product
intermedi
level
figur
verifi
whether
l
lacti
abl
modifi
siga
level
physiolog
scenario
measur
siga
level
day
oral
administr
l
lacti
l
lacti
ncdo
alter
siga
product
figur
discard
possibl
iga
modul
might
regulatori
mechan
mediat
l
lacti
identifi
potenti
mechan
l
lacti
ncdo
exert
benefici
effect
cytokin
profil
colon
tissu
evalu
day
oral
administr
significantli
increas
level
day
level
cytokin
higher
day
dss
dss
group
figur
exposur
dss
led
increas
level
day
l
lacti
affect
phenomenon
figur
despit
level
chang
due
dss
l
lacti
treatment
figur
level
reduc
day
dss
dss
group
figur
affect
dss
l
lacti
figur
antiinflammatori
cytokin
significantli
decreas
dsstreat
group
ncdo
group
day
figur
lastli
level
increas
dsstreat
mice
day
level
ncdo
mice
maintain
level
similar
control
group
intestin
inflamm
dssinduc
coliti
trigger
microbi
antigen
induct
oral
toler
microbiota
could
one
potenti
mechan
l
lacti
ncdo
stimul
immun
system
oral
toler
maintain
mainli
treg
cell
analys
chang
cell
mesenter
lymph
node
spleen
mice
l
lacti
ncdo
alter
number
activ
cell
mesenter
lymph
node
howev
treatment
enhanc
number
activ
cell
spleen
figur
suggest
l
lacti
product
abl
activ
cell
vivo
popul
regulatori
cell
affect
dss
treatment
figur
result
observ
treg
data
shown
nevertheless
level
regulatori
cell
increas
mesenter
lymph
node
spleen
ncdo
mice
dc
popul
describ
tolerogen
express
dc
analys
mesenter
lymph
node
spleen
find
differ
cell
mesenter
lymph
node
howev
frequenc
cell
increas
spleen
coliti
dss
group
enhanc
mice
dss
group
studi
show
cultur
supernat
l
lacti
ncdo
abl
reduc
product
cell
stimul
thu
l
lacti
ncdo
strain
immunomodulatori
effect
iec
vitro
conclus
base
previou
find
trigger
transcript
activ
proinflammatori
gene
intestin
epitheli
cell
iec
mani
other
express
shown
transcript
factor
overactiv
mucos
cell
ibd
patient
thu
search
altern
treatment
ibd
abil
inhibit
secret
pathway
product
good
paramet
consid
sever
probiot
mainli
commens
lactobacillu
rhamnosu
gg
lactobacillu
reuteri
bifidobacterium
longum
influenc
downstream
cytokin
secret
iec
l
lacti
littl
publish
cocultur
l
lacti
subsp
cremori
fc
cell
result
signific
downregul
mrna
express
cell
inhibit
nuclear
transloc
cell
interestingli
found
inhibit
depend
strain
use
assay
similar
result
report
santo
rocha
et
al
also
found
straindepend
immunomodulatori
effect
dairi
bacteria
lactobacillu
delbrueckii
studi
show
use
vitro
assay
l
lacti
ncdo
strain
immunomodulatori
effect
iec
conclus
base
fact
trigger
transcript
activ
proinflammatori
gene
iec
thu
activ
transcript
factor
includ
nuclear
factor
induc
increas
express
proinflammatori
mediat
mani
other
due
interest
vitro
result
l
lacti
ncdo
appear
potenti
use
probiot
ibd
therapi
thu
vivo
experi
perform
evalu
effect
strain
dssinduc
murin
model
coliti
shown
l
lacti
ncdo
abl
amelior
second
coliti
cycl
induc
dss
studi
intestin
injuri
assess
varieti
method
includ
bodi
weight
colon
length
histolog
base
macroscop
microscop
criteria
l
lacti
ncdo
inhibit
colon
injuri
experiment
time
period
resembl
typic
remiss
period
ibd
chose
administ
bacteria
onset
coliti
close
resembl
clinic
scenario
possibl
predict
diseas
start
becam
activ
l
lacti
ncdo
also
improv
macroscop
symptom
coliti
especi
diarrhea
day
howev
time
point
colon
length
histolog
sign
amelior
analysi
two
time
point
day
allow
us
separ
two
differ
scenario
l
lacti
exert
effect
opt
investig
second
scenario
coliti
improv
evid
second
cycl
coliti
sever
studi
shown
consumpt
probiot
associ
increas
gut
siga
level
could
promot
integr
gut
immunolog
barrier
limit
penetr
bacteria
commens
pathogen
host
tissu
particularli
relev
dss
model
coliti
dss
toxic
gut
epitheli
cell
enhanc
bacteri
transloc
howev
l
lacti
alter
siga
product
oral
treatment
cytokin
produc
gut
mucosa
greatli
influenc
result
immunolog
outcom
product
antiinflammatori
cytokin
induc
mucos
toler
high
level
proinflammatori
cytokin
induc
protect
immun
respons
inflamm
intrigu
aspect
probioticinduc
modul
immun
respons
effect
probiot
cytokin
product
studi
investig
effect
l
lacti
ncdo
cytokin
product
kimoto
et
al
show
l
lacti
induc
immun
respons
vitro
pavan
et
al
observ
signific
increas
product
ilea
mice
fed
l
lacti
studi
l
lacti
ncdo
alter
product
colon
tissu
found
increas
level
colon
mice
fed
l
lacti
ncdo
coliti
induct
acut
situat
chemic
induc
coliti
mice
higher
level
inflamm
wild
type
mice
appear
enhanc
mucos
repair
epitheli
reconstitut
therefor
specul
l
lacti
could
promot
epitheli
repair
via
product
result
ultim
prevent
diarrhea
discuss
gener
thought
proinflammatori
role
intestin
howev
neutralis
aggrav
acut
dssinduc
coliti
mice
suggest
protect
role
colon
inflamm
studi
level
diminish
mice
receiv
second
cycl
dss
level
affect
oral
administr
l
lacti
ncdo
like
import
cytokin
involv
shape
immun
respons
gut
mucosa
mice
spontan
develop
gut
inflamm
present
studi
second
cycl
coliti
level
decreas
colon
dsstreat
mice
l
lacti
ncdo
administr
prevent
reduct
thu
mainten
level
seem
respons
least
part
antiinflammatori
effect
l
lacti
ncdo
present
studi
oral
administr
l
lacti
ncdo
improv
aberr
level
induc
dss
approxim
control
level
agreement
nishitani
et
al
demonstr
lactococcu
lacti
cremori
drastic
reduc
mrna
express
major
proinflammatori
cytokin
involv
dssinduc
coliti
model
investig
effect
l
lacti
cell
popul
evalu
cell
mesenter
lymph
node
spleen
mice
treat
l
lacti
ncdo
chronic
coliti
ibd
gener
believ
driven
cell
thought
associ
increas
inflammatori
cytokin
especi
cell
specialis
regulatori
cell
counterbal
proinflammatori
respons
number
activ
cell
express
earliest
induc
cell
surfac
glycoprotein
acquir
lymphoid
activ
analys
coliti
induct
number
cell
increas
spleen
mice
fed
l
lacti
ncdo
therefor
l
lacti
product
abl
activ
cell
transfer
cell
innat
immun
activ
leukopen
mice
report
induc
coliti
wherea
cotransf
cell
prevent
diseas
induct
cell
popul
identifi
regulatori
cell
subset
despit
antiinflammatori
activ
l
lacti
ncdo
administr
enhanc
frequenc
regulatori
cell
popul
howev
anoth
type
peripher
induc
treg
cell
characteris
surfac
express
lap
ntermin
propeptid
tgfbeta
precursor
increas
mesenter
lymph
node
spleen
mice
treat
l
lacti
ncdo
previous
di
giacinto
et
al
show
administr
probiot
vsl
remiss
period
tnbsinduc
coliti
increas
number
regulatori
cell
essenti
protect
effect
probiot
dendrit
cell
modul
cell
differenti
effector
regulatori
cell
profil
dc
evalu
shown
previous
dc
induc
treg
cell
intestin
mucosa
chemic
induc
coliti
model
found
increas
number
dc
mice
treat
dss
howev
oral
administr
l
lacti
ncdo
enhanc
number
dc
greater
extent
gyu
jeon
et
al
recent
show
bifidobacterium
breve
induc
develop
cell
effect
mediat
dc
thu
l
lacti
ncdo
may
trigger
regulatori
phenotyp
dc
drive
expans
induc
regulatori
cell
therefor
propos
work
model
l
lacti
ncdo
activ
vivo
depict
figur
conclus
show
l
lacti
ncdo
antiinflammatori
activ
vitro
cultur
intestin
epitheli
cell
iec
dssinduc
model
coliti
moreov
show
effect
vitro
screen
method
identif
probiot
strain
l
lacti
test
vivo
mechan
involv
antiinflammatori
effect
includ
modul
colon
cytokin
well
expans
regulatori
cell
antiinflammatori
dc
taken
togeth
result
suggest
commens
also
dairi
bacteria
part
diet
probiot
effect
natur
l
lacti
ncdo
compon
respons
antiinflammatori
effect
investig
three
l
lacti
strain
use
studi
l
lacti
subsp
lacti
ncdo
l
lacti
subsp
lacti
l
lacti
subsp
cremori
grown
medium
difco
contain
glucos
without
agit
medium
solidifi
agar
hour
cell
atcc
human
colon
adenocarcinoma
cell
line
cultur
rpmi
medium
sigma
supplement
vv
fetal
bovin
serum
fb
gibco
mm
lglutamin
mm
nonessenti
amino
acid
mm
sodium
pyruv
solut
atmospher
contain
cell
seed
cellswel
plate
incub
hour
treatment
secret
proinflammatori
cytokin
cell
induc
addit
human
recombin
bd
bioscienc
final
concentr
ngml
l
lacti
cultur
stationari
phase
growth
fraction
centrifug
supernat
cell
fraction
coincub
cell
bacteri
cell
wash
time
pb
mml
nacl
mml
kcl
mml
mml
ad
multipl
infect
moi
supernat
filter
final
concentr
vv
cell
treat
use
control
hour
coincub
supernat
cell
cultur
collect
store
analysi
level
measur
use
human
elisa
kit
bd
bioscienc
follow
manufactur
instruct
data
three
independ
experi
analys
chemic
coliti
induc
replac
drink
water
mice
wv
aqueou
solut
dextran
sodium
sulphat
dss
mp
biomed
consecut
day
subsequ
mice
receiv
either
medium
dss
group
l
lacti
ncdo
dss
group
oral
four
consecut
day
fresh
total
cultur
bacteria
plu
supernat
stationari
phase
growth
prepar
daili
offer
mice
mous
drank
approxim
ml
cultur
per
day
data
shown
total
dose
bacteria
per
mous
estim
bacteriaday
mice
sacrif
either
day
immedi
follow
oral
treatment
second
dss
cycl
day
control
group
mice
receiv
l
lacti
alon
throughout
experiment
period
mice
unlimit
access
food
schemat
represent
experiment
procedur
shown
figur
dssinduc
coliti
assess
macroscop
score
three
major
clinic
loss
diarrhea
rectal
day
day
describ
cooper
et
al
bodi
weight
loss
calcul
differ
initi
actual
weight
diarrhea
determin
assess
mucusfaec
materi
adher
anal
fur
confirm
presenc
absenc
faecal
pellet
format
continu
fluid
faecal
materi
colon
rectal
bleed
defin
diarrhea
contain
visibl
blood
gross
rectal
bleed
three
major
clinic
sign
weight
loss
diarrhea
occultgross
bleed
score
separ
macroscop
score
calcul
score
clinic
sign
use
follow
formula
weight
loss
score
diarrhea
score
rectal
bleed
score
mice
sacrif
spleen
mesenter
lymph
node
colon
excis
spleen
mesenter
lymph
node
use
cell
popul
analysi
colon
sampl
fix
formalin
process
histolog
analysi
hematoxylineosinstain
section
blindli
score
base
previous
describ
semiquantit
score
system
follow
featur
grade
extent
destruct
normal
mucos
architectur
normal
mild
moder
extens
damag
respect
presenc
degre
cellular
infiltr
normal
mild
moder
transmur
infiltr
respect
extent
muscl
thicken
normal
mild
moder
extens
thicken
respect
presenc
absenc
crypt
abscess
absent
present
presenc
absenc
goblet
cell
deplet
absent
present
score
featur
sum
maximum
possibl
score
colon
sampl
weigh
homogenis
pb
contain
vv
mm
phenylmethylsulphonyl
fluorid
mm
benzethonium
chlorid
mm
edta
kiu
aprotinin
use
tissu
homogenis
mg
tissueml
buffer
suspens
centrifug
g
min
supernat
collect
cytokin
assay
plate
coat
purifi
monoclon
antibodi
reactiv
cytokin
bdpharmingen
overnight
follow
day
well
wash
supernat
ad
plate
incub
overnight
third
day
biotinyl
monoclon
antibodi
cytokin
ad
plate
incub
hour
room
temperatur
colour
develop
room
temperatur
orthophenylenediamin
mgml
vv
substrat
sodium
citrat
buffer
reaction
interrupt
addit
n
absorb
measur
nm
use
micropl
reader
biorad
level
siga
determin
elisa
briefli
plate
nunc
coat
ig
goat
antimous
unlb
antibodi
coat
buffer
ph
overnight
well
wash
block
pb
contain
casein
h
room
temperatur
sampl
ad
plate
incub
h
plate
wash
peroxidasestreptavidin
goat
antimous
igahrp
southern
biotechnolog
dilut
ad
plate
incub
h
colour
develop
room
temperatur
orthophenylenediamin
mgml
sigma
substrat
sodium
citrat
buffer
reaction
interrupt
addit
n
absorb
measur
nm
use
elisa
micropl
reader
biorad
fluorescein
isothiocyanateconjug
fitc
mab
phycoerythrin
pe
conjug
mab
biotinyl
antibodi
utilis
purchas
bd
bioscienc
biotinyl
antihuman
lap
antibodi
purchas
r
system
surfac
stain
perform
accord
standard
procedur
densiti
cell
isol
spleen
mesenter
lymph
node
per
well
sampl
analys
facscan
instrument
bd
result
analys
flowjo
softwar
tree
star
inc
result
express
mean
standard
error
mean
sem
normal
distribut
sampl
confirm
test
signific
differ
among
group
determin
student
ttest
analysi
varianc
anova
tukey
post
test
mean
consid
significantli
differ
p
cox
cyclooxygenas
cd
crohn
diseas
dc
dendrit
cell
dss
dextran
sodium
sulphat
git
gastrointestin
tract
ibd
inflammatori
bowel
diseas
iec
intestin
epitheli
cell
il
interleukin
ifn
interferon
lab
lactic
acid
bacteria
lap
latencyassoci
peptid
nuclear
factor
siga
secretori
iga
tgf
transform
growth
factor
tnf
tumour
necrosi
factor
treg
regulatori
cell
uc
ulcer
coliti
author
declar
compet
interest
conceiv
design
experi
acg
csr
amcf
dcc
jgl
va
perform
experi
tdl
acg
csr
tgm
dnc
analys
data
tdl
acg
al
vbp
km
wrote
paper
tdl
acg
jgl
amcf
va
author
read
approv
final
manuscript
ana
maria
caetano
faria
anderson
miyoshi
share
credit
senior
authorship
